FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2795499024> ?p ?o ?g. }

• W2795499024 abstract "Background More than 400,000 cases of oropharyngeal squamous cell cancer (OPSCC) are diagnosed every year worldwide and this is rising. Much of the increase has been attributed to human papillomavirus (HPV). HPV‐positive OPSCC patients are often younger and have significantly improved survival relative to HPV‐negative patients. Traditional management of OPSCC has been with radiotherapy with or without chemotherapy, as this was shown to have similar survival to open surgery but with significantly lower morbidity. Techniques have evolved, however, with the development of computerised planning and intensity‐modulated radiotherapy, and of minimally invasive surgical techniques. Acute and late toxicities associated with chemoradiotherapy are a significant burden for OPSCC patients and with an ever‐younger cohort, any strategies that could decrease treatment‐associated morbidity should be investigated. Objectives To assess the effects of de‐intensified adjuvant (chemo)radiotherapy in comparison to standard adjuvant (chemo)radiotherapy in patients treated with minimally invasive transoral surgery (transoral robotic surgery or transoral laser microsurgery) for resectable HPV‐positive oropharyngeal squamous cell carcinoma. Search methods The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 26 April 2018. Selection criteria Randomised controlled trials (RCTs) in patients with carcinoma of the oropharynx (as defined by the World Health Organization classification C09, C10). Cancers included were primary HPV‐positive squamous cell tumours originating from the oropharyngeal mucosa. Tumours were classified as T1‐4a with or without nodal spread and with no evidence of distant metastatic spread. The intervention was minimally invasive transoral surgery followed by de‐intensified adjuvant therapy (either omission of chemotherapy or reduced‐dose radiotherapy). The comparator was minimally invasive transoral surgery followed by standard concurrent chemoradiotherapy or standard‐dose radiotherapy. The treatments received were of curative intent and patients had not undergone any prior intervention, other than diagnostic biopsy. Data collection and analysis We used the standard methodological procedures expected by Cochrane. Our primary outcomes were overall survival (disease‐related survival was to be studied where possible) and disease‐free survival, measured at one, two, three and five years. Our secondary outcomes included assessment of swallowing ability and voice, measured at one, six, 12 and 24 months. We planned to use GRADE to assess the quality of evidence for each outcome. Main results We did not identify any completed RCTs that met our inclusion criteria. However, three eligible studies are in progress: ADEPT is a phase III trial comparing postoperative radiotherapy with or without cisplatin in HPV‐positive T1‐4a OPSCC patients. Included patients must have received minimally invasive surgery and demonstrated extra‐capsular spread from disease in the neck. ECOG‐E3311 is a phase II trial of treatment for HPV‐positive locally advanced OPSCC (stages III‐IVa + IVb without distant metastasis). Patients are stratified after minimally invasive surgery. Medium‐risk patients are randomised to either standard or reduced‐dose radiotherapy. PATHOS is a phase III trial of treatment for HPV‐positive OPSCC (T1‐3, N0‐2b). Patients are stratified after minimally invasive surgery. Medium‐risk patients are randomised to either standard or reduced‐dose radiotherapy. High‐risk patients are randomised to radiotherapy with or without concurrent cisplatin. Authors' conclusions This review highlights the current lack of high‐quality randomised controlled trials studying treatment de‐escalation after minimally invasive surgery in patients with HPV‐positive OPSCC. However, trials that will meet the inclusion criteria for this review are in progress with results expected between 2021 and 2023." @default.
• W2795499024 created "2018-04-13" @default.
• W2795499024 creator A5002036861 @default.
• W2795499024 creator A5032526919 @default.
• W2795499024 creator A5040666240 @default.
• W2795499024 creator A5043598587 @default.
• W2795499024 creator A5045836778 @default.
• W2795499024 creator A5085288606 @default.
• W2795499024 date "2018-12-14" @default.
• W2795499024 modified "2023-10-17" @default.
• W2795499024 title "De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma" @default.
• W2795499024 cites W1558921590 @default.
• W2795499024 cites W1587143876 @default.
• W2795499024 cites W1972387603 @default.
• W2795499024 cites W1988735862 @default.
• W2795499024 cites W1994510965 @default.
• W2795499024 cites W1998375528 @default.
• W2795499024 cites W1999719546 @default.
• W2795499024 cites W2011114729 @default.
• W2795499024 cites W2023840357 @default.
• W2795499024 cites W2031309489 @default.
• W2795499024 cites W2036005555 @default.
• W2795499024 cites W2036697383 @default.
• W2795499024 cites W2043453187 @default.
• W2795499024 cites W2045508920 @default.
• W2795499024 cites W2050791888 @default.
• W2795499024 cites W2051044590 @default.
• W2795499024 cites W2064187806 @default.
• W2795499024 cites W2070669025 @default.
• W2795499024 cites W2075284500 @default.
• W2795499024 cites W2075642745 @default.
• W2795499024 cites W2085503214 @default.
• W2795499024 cites W2089600839 @default.
• W2795499024 cites W2101440362 @default.
• W2795499024 cites W2101493256 @default.
• W2795499024 cites W2102282815 @default.
• W2795499024 cites W2107283868 @default.
• W2795499024 cites W2110311036 @default.
• W2795499024 cites W2110664940 @default.
• W2795499024 cites W2111442242 @default.
• W2795499024 cites W2127605299 @default.
• W2795499024 cites W2128164335 @default.
• W2795499024 cites W2138779768 @default.
• W2795499024 cites W2139376220 @default.
• W2795499024 cites W2139595853 @default.
• W2795499024 cites W2140753782 @default.
• W2795499024 cites W2141898515 @default.
• W2795499024 cites W2142222095 @default.
• W2795499024 cites W2143680521 @default.
• W2795499024 cites W2145640178 @default.
• W2795499024 cites W2148028028 @default.
• W2795499024 cites W2151269016 @default.
• W2795499024 cites W2158534818 @default.
• W2795499024 cites W2164710273 @default.
• W2795499024 cites W2280894559 @default.
• W2795499024 cites W2510964327 @default.
• W2795499024 cites W2531397610 @default.
• W2795499024 cites W2559810691 @default.
• W2795499024 cites W2795499024 @default.
• W2795499024 cites W2805311140 @default.
• W2795499024 cites W2888118889 @default.
• W2795499024 cites W4231621249 @default.
• W2795499024 cites W4233206098 @default.
• W2795499024 doi "https://doi.org/10.1002/14651858.cd012939.pub2" @default.
• W2795499024 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6517188" @default.
• W2795499024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30550641" @default.
• W2795499024 hasPublicationYear "2018" @default.
• W2795499024 type Work @default.
• W2795499024 sameAs 2795499024 @default.
• W2795499024 citedByCount "18" @default.
• W2795499024 countsByYear W27954990242018 @default.
• W2795499024 countsByYear W27954990242019 @default.
• W2795499024 countsByYear W27954990242020 @default.
• W2795499024 countsByYear W27954990242021 @default.
• W2795499024 countsByYear W27954990242022 @default.
• W2795499024 countsByYear W27954990242023 @default.
• W2795499024 crossrefType "journal-article" @default.
• W2795499024 hasAuthorship W2795499024A5002036861 @default.
• W2795499024 hasAuthorship W2795499024A5032526919 @default.
• W2795499024 hasAuthorship W2795499024A5040666240 @default.
• W2795499024 hasAuthorship W2795499024A5043598587 @default.
• W2795499024 hasAuthorship W2795499024A5045836778 @default.
• W2795499024 hasAuthorship W2795499024A5085288606 @default.
• W2795499024 hasBestOaLocation W27954990242 @default.
• W2795499024 hasConcept C121608353 @default.
• W2795499024 hasConcept C126322002 @default.
• W2795499024 hasConcept C141071460 @default.
• W2795499024 hasConcept C143998085 @default.
• W2795499024 hasConcept C168563851 @default.
• W2795499024 hasConcept C2778424827 @default.
• W2795499024 hasConcept C2908642260 @default.
• W2795499024 hasConcept C509974204 @default.
• W2795499024 hasConcept C71924100 @default.
• W2795499024 hasConceptScore W2795499024C121608353 @default.
• W2795499024 hasConceptScore W2795499024C126322002 @default.
• W2795499024 hasConceptScore W2795499024C141071460 @default.
• W2795499024 hasConceptScore W2795499024C143998085 @default.
• W2795499024 hasConceptScore W2795499024C168563851 @default.
• W2795499024 hasConceptScore W2795499024C2778424827 @default.
• W2795499024 hasConceptScore W2795499024C2908642260 @default.

• next